Structure-based virtual screening, in vitro and in vivo analyses identified kaempferol 3-gentiobioside as an FXR partial agonist protecting against cholestatic liver disease

Bioorganic & Medicinal Chemistry · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles